Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug binding sites. Over the past 40 years, great eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chunxiao, Guan, Xiaoqing, Zhang, Xinuo, Luan, Xin, Song, Zhengbo, Cheng, Xiangdong, Zhang, Weidong, Qin, Jiang-Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351107/
https://www.ncbi.nlm.nih.gov/pubmed/35922812
http://dx.doi.org/10.1186/s12943-022-01629-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351107/
https://www.ncbi.nlm.nih.gov/pubmed/35922812
http://dx.doi.org/10.1186/s12943-022-01629-2

Ejemplares similares